PET developer Positron’s year of hibernation was reflected in the company’s 1998 financial results (end-December), which were released this month. The Houston company sold no systems in 1998, compared with one sale of $1.1 million the year
PET developer Positrons year of hibernation was reflected in the companys 1998 financial results (end-December), which were released this month. The Houston company sold no systems in 1998, compared with one sale of $1.1 million the year before. The vendor reported revenues of $2 million last year, thanks to service and fee-per-scan revenues, while in 1997 Positron had sales of $3.5 million. Positron did have some good news for the year, however. Thanks to cost-cutting efforts, its net loss decreased to $724,000, an improvement on last years loss of $4.5 million.
Yet despite modest results for 1998, Positron may be gaining strength. In April 1998, the company was unsure it could continue as a going concern; in May, it signed an agreement with South San Francisco CT developer Imatron, in which Imatron acquired a majority stake in Positron and began feeding the company working capital (SCAN 5/13/98). Imatrons purchase was finalized early this year, and since then Imatron has been negotiating with third-party investors to help resuscitate the company (SCAN 2/3/99).
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Study Shows Enhanced Diagnosis of Coronary Artery Stenosis with Photon-Counting CTA
July 10th 2025In a new study comparing standard resolution and ultra-high resolution modes for patients undergoing coronary CTA with photon-counting detector CT, researchers found that segment-level sensitivity and accuracy rates for diagnosing coronary artery stenosis were consistently > 89.6 percent.
FDA Expands Approval of MRI-Guided Ultrasound Treatment for Patients with Parkinson’s Disease
July 9th 2025For patients with advanced Parkinson’s disease, the expanded FDA approval of the Exablate Neuro platform allows for the use of MRI-guided focused ultrasound in performing staged bilateral pallidothalamic tractotomy.